Comparative Pharmacology
Head-to-head clinical analysis: REVUFORJ versus TOFACITINIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REVUFORJ versus TOFACITINIB.
REVUFORJ vs TOFACITINIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
REVUFORJ (revumenib) is a potent and selective oral inhibitor of the menin-KMT2A (MLL) protein-protein interaction. It blocks the binding of menin to the N-terminus of KMT2A fusion proteins and mutant NPM1, thereby inhibiting the transcriptional activation of downstream target genes (e.g., HOXA9, MEIS1) that drive leukemogenesis.
Janus kinase (JAK) inhibitor, primarily inhibiting JAK1 and JAK3, thereby modulating the JAK-STAT signaling pathway to reduce cytokine production and immune cell activation.
Oral, 500 mg twice daily.
5 mg orally twice daily; extended-release formulation 11 mg orally once daily. For rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis. For ulcerative colitis, induction: 10 mg orally twice daily for 8 weeks, then maintenance 5 mg twice daily.
None Documented
None Documented
Clinical Note
moderateTofacitinib + Digoxin
"Tofacitinib may increase the bradycardic activities of Digoxin."
Clinical Note
moderateTofacitinib + Bendroflumethiazide
"Tofacitinib may increase the bradycardic activities of Bendroflumethiazide."
Clinical Note
moderateTofacitinib + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Tofacitinib."
Clinical Note
moderateTofacitinib + Erythromycin
Terminal elimination half-life is approximately 40 hours in healthy subjects; extended to 72 hours in patients with moderate hepatic impairment (Child-Pugh B), requiring dose adjustment.
Terminal half-life approximately 3.3 hours in healthy volunteers. In patients with rheumatoid arthritis, effective half-life ~3-6 hours due to reversible binding to JAK enzymes. No significant accumulation at steady state.
Primarily renal excretion of unchanged drug (approximately 70%) and fecal excretion (approximately 20%) via biliary elimination; minimal metabolism.
Primarily renal (70%) with 30% excreted unchanged in urine. Fecal elimination accounts for 20% (<1% unchanged). Minor biliary excretion.
Category C
Category D/X
JAK Inhibitor
JAK Inhibitor
"The metabolism of Erythromycin can be decreased when combined with Tofacitinib."